Cervical cancer is the third most common type of cancer among women worldwide, accounting for 9% of all new cancer cases among females in 2008 ([@bib10]). Although screening for premalignant stages of cervical cancer and vaccination with the available human papillomavirus (HPV)-vaccines are good options to prevent cervical carcinogenesis, treatment options are limited when women present with advanced cancer stages. Partly, this is because the mechanisms involved in tumour cell invasion and metastasis formation, which strongly predict mortality rates, are not fully understood. Furthermore, markers that accurately predict response to therapy are limited. Additional predictive molecular markers for lymph node metastases and disease-free survival may help to elucidate these mechanisms.

A promising new marker is the CXC chemokine receptor (CXCR) 7. CXC chemokine receptor 7 is transcribed from the *RDC1*-gene on chromosome 2, where the genes encoding CXCR1, CXCR2 and CXCR4 are also localised ([@bib1]). CXC chemokine receptor 7 is strongly expressed in many different tumour types and on tumour-associated vasculature, whereas expression in most normal tissues is weak or absent. The CXCR7 is involved in cell survival, cell adhesion, tumour development and metastases formation ([@bib2]; [@bib15]). Expression of CXCR7 has not been determined in cervical cancer, but has been associated with a higher tumour grade and more aggressive tumour growth in other cancer types, such as prostate cancer, non-small cell lung cancer, breast cancer, glioma and hepatocellular carcinoma ([@bib15]; [@bib20]; [@bib9]; [@bib7]; [@bib22]). However, most studies have been performed on tumour cell lines and mouse models, and studies addressing the association between CXCR7 expression and prognosis in patient-derived tumour material are limited.

Two ligands bind to CXCR7, namely CXCL11 (interferon-inducible T-cell *α* chemoattractant) and CXCL12 (stromal cell-derived factor-1). In cell lines, activation of CXCR7 by CXCL12 induced *trans*-endothelial migration, whereas CXCR7 antagonists and CXCL11 both inhibited cellular migration ([@bib21]). Furthermore, CXCL12 expression was associated with overall and disease-free survival in pancreas carcinoma, suggesting that CXCL12 is the predominant ligand associated with CXCR7-mediated metastasis formation ([@bib14]).

Conflicting results have been published on the intracellular signalling pathways of CXCR7, as ligand binding does not result in typical CXC receptor Gi-mediated signalling ([@bib19]). It is still unclear whether the receptor is able to activate other signal transduction pathways. It has been proposed that CXCR7 heterodimerisation with other signalling receptors such as the epidermal growth factor receptor (EGFR) or CXCR4 is required to induce intracellular signalling ([@bib6]; [@bib3]; [@bib18]). Both EGFR and CXCR4 expression have been shown to be associated with lymph node metastases and disease-free survival in cervical cancer ([@bib11]; [@bib12]; [@bib16]).

The aim of the present study was to determine protein expression of CXCR7, its putative co-receptors EGFR and CXCR4, its main ligand CXCL12, their co-dependency and their association with survival in cervical cancer patients. Therefore, we immunohistochemically determined CXCR7, EGFR, CXCR4 and CXCL12 expression, and assessed the association between protein expression and patient characteristics. Furthermore, we analysed whether (co-)expression of CXCR7, EGFR and CXCR4 was associated with disease-specific and disease-free survival.

Materials and methods
=====================

Subjects
--------

Formalin-fixed, paraffin-embedded primary tumour tissue samples from 103 cervical cancer patients who underwent radical hysterectomy with lymphadenectomy between January 1985 and December 1999 were collected from the archives of the Department of Pathology, Leiden University Medical Center (Leiden, the Netherlands). Patients had not received radiotherapy or chemotherapy before surgery. Postoperative radiotherapy was indicated in patients with lymph node metastasis, parametrial involvement or positive resection margins. Clinical and follow-up data were taken from patient medical records. Disease-specific survival and disease-free survival were assessed to determine the time to cancer-related death and disease recurrence, respectively. Disease-specific survival time was assessed from the date of surgery to the date of cancer-related death or the date of the last follow-up visit for censored observations. For disease-specific survival, patients who died of a cause unrelated to cervical cancer were considered as censored observations at the date of death. The end point for disease-free survival was the date of local or regional recurrence or the date of distant metastasis.

Tumours were HPV-typed by general primer PCR and sequencing, as described by [@bib13]). In addition to the tumour samples, two specimens of normal cervical epithelium were obtained from two patients with no history of cervical cancer. This number of healthy tissue samples was sufficient, as the staining of CXCR4, CXCR7 and CXCL12 was expected to be similar for all normal cervical epithelium specimens. Tissue samples were used according to the guidelines of the Ethical Committee of the Leiden University Medical Center.

Immunohistochemistry
--------------------

For immunohistochemical analysis, 4 *μ*m tissue microarray (TMA) slides consisting of triplicate punches of 103 cervical cancer patients were deparaffinised and rehydrated. Endogenous peroxidase was blocked with 0.3% hydrogen peroxide (H~2~O~2~) for 20 min. Antigen retrieval was performed in 0.01 ℳ citrate buffer (pH=6.0, 12 min, microwave oven). Subsequently, slides were incubated overnight at room temperature with anti-CXCR4 (1 : 600, IgG2a, clone 2F1, Abnova, Heidelberg, Germany), anti-CXCR7 (1 : 50, IgG1, clone 11G8, R&D Systems, Abingdon, UK) or anti-CXCL12 (1 : 50, IgG1, clone 79018, R&D Systems), diluted in phosphate-buffered saline (PBS) containing 1% bovine serum albumin. After washing with PBS, the TMA slides were incubated for 30 min with BrightVision-Poly/HRP (Immunologic, Duiven, the Netherlands). Immunoreactions were visualised using 0.5% 3,3′-diamino-benzidine-tetra-hydrochloride and 0.002% H~2~O~2~ in Tris-HCl, after which the slides were counterstained with haematoxylin. Immunoreactivity was scored as negative, weak, moderate or strong staining intensity. Immunohistochemistry for EGFR was performed as previously described, and EGFR was scored for membrane staining intensity ([@bib16]).

Statistical analyses
--------------------

Statistical analyses were performed using the SPSS program (Version 17.0 for Windows; SPSS Inc., Chicago, IL, USA). Significance tests were two-sided and statistical significance was assumed when *P*\<0.05, corresponding to 95% confidence intervals (CI). To assess whether CXCR7 expression was associated with expression of its ligand CXCL12 or its proposed co-receptors EGFR and CXCR4, the Spearman\'s rank correlation test was performed, as the intensity scores for CXCR7, EGFR, CXCR4 and CXCL12 were ordinal. The *χ*^2^ test was used to determine whether CXCR7, EGFR, CXCR4 and CXCL12 expression was associated with clinicopathological characteristics, with protein expression data recoded into binary variables. Univariate Cox-regression analysis was performed to assess the association between clinicopathological parameters, CXCR7, EGFR, CXCR4 and CXCL12 expression, and disease-free survival. All analyses were repeated for disease-specific survival. Multivariate Cox-regression analysis was performed to determine whether CXCR7 expression was independently associated with disease-free survival, when correcting for HPV-type, histopathological diagnosis, tumour size, infiltration depth, parametrial invasion, vasoinvasion, lymph node metastasis, resection margins and postoperative radiotherapy. Corresponding survival curves were estimated by the Kaplan-Meier method.

Results
=======

Patient characteristics in relation to CXCR7, EGFR, CXCR4 and CXCL12 expression in cervical cancer
--------------------------------------------------------------------------------------------------

Immunohistochemical staining of CXCR7, CXCR4 and CXCL12 was observed to be both cytoplasmic and membranous in cervical cancer specimens. Normal cervical epithelium stained weakly for CXCR7, CXCR4 and CXCL12, with strong CXCL12 expression in cells of the basal layer. Representative examples of positive and negative CXCR7, EGFR, CXCR4 and CXCL12 cervical cancer specimens are shown in [Figure 1](#fig1){ref-type="fig"}. The distribution of staining intensities is shown in [Table 1](#tbl1){ref-type="table"}. CXC chemokine receptor 7, EGFR and CXCL12 had a wider range in staining intensity, when compared with CXCR4, as no strong positives were observed for CXCR4. To assess whether CXCR7 expression was associated with expression of its ligand CXCL12 or its proposed co-receptors EGFR and CXCR4, the Spearman\'s rank correlation coefficient (*ρ*; rho) was determined. CXC chemokine receptor 7 expression was significantly correlated with EGFR expression (*ρ*=0.272, *P*=0.009), but not with CXCR4 expression (*ρ*=0.117, *P*=0.259) or CXCL12 expression (*ρ*=−0.028, *P*=0.790). Compared with an ideal correlation of 1, the observed Spearman\'s *ρ* of 0.272 indicates a moderate correlation.

Clinicopathological characteristics of the 103 cervical cancer patients are summarised in [Table 2](#tbl2){ref-type="table"}. The median age at the time of diagnosis was 48 years (range, 24--87). Positive CXCR7 expression was associated with tumour size ⩾40 mm (odds ratio (OR)=2.9, 95% confidence interval (CI) 1.2--6.8, *P*=0.013) and lymph node positivity at the time of surgery (OR=5.7, 95% CI 2.0--16.1, *P*=0.001). CXC chemokine receptor 7 expression was observed more frequently in squamous carcinoma than in adeno-/adenosquamous carcinoma (OR=2.6, 95% CI 1.1--6.0, *P*=0.025). Both EGFR and CXCR4 expression were observed more frequently in squamous/adenosquamous carcinoma than in adenocarcinoma (OR 26.6, 95% CI 3.3--217.4, *P*\<0.001 and OR=6.4, 95% CI 1.6--25.7, *P*=0.008, respectively). No other associations were observed between CXCR7, CXCR4, CXCL12 and clinicopathological characteristics. As previously described, EGFR expression was associated with tumour size, parametrial invasion, vasoinvasion and lymph node metastasis ([@bib16]).

Disease-specific and disease-free survival for CXCR7, EGFR, CXCR4 and CXCL12
----------------------------------------------------------------------------

Median follow-up time was 137 months (range 5--266) for all patients and 156 months (range 8--266) for patients alive at the time of data collection. Of the 24 patients with disease recurrence, a combination of local recurrences (*n*=4), regional recurrences (*n*=3) and distant metastases (*n*=20) was observed. Of the 34 patients who died during the follow-up period, 22 deaths could be attributed to cervical cancer. Five-year disease-free and disease-specific survival rates for the whole group were 77% (s.e.=4) and 79% (s.e.=4), respectively. Univariate Cox-regression analysis for all clinicopathological characteristics and disease-free survival is shown in [Table 2](#tbl2){ref-type="table"}. Multivariate regression analysis for all clinicopathological characteristics showed that only tumour size (hazard ratio (HR)=4.8, 95% CI 1.8--12.3, *P*=0.001) and lymph node metastasis (HR=5.4, 95% CI 2.3--12.7, *P*\<0.001) were independently associated with disease-free survival.

Univariate Cox-regression analysis for CXCR7 showed a strong association between positive CXCR7 expression and disease recurrence, with 63% *vs* 90% disease-free survival for CXCR7-positive and CXCR7-negative cases, respectively, (HR=4.3, 95% CI 1.7--11.0, *P*=0.002, [Figure 2A](#fig2){ref-type="fig"}, [Table 3](#tbl3){ref-type="table"}). CXC chemokine receptor 7 expression was also associated with disease-specific survival (HR=3.9, 95% CI 1.5--10.2, *P*=0.005). CXC chemokine receptor 4 and CXCL12 expression were not associated with disease-free ([Table 3](#tbl3){ref-type="table"}) nor disease-specific survival (data not shown). There was a trend for a positive association between EGFR expression and disease-free survival (HR=2.3, 95% CI 0.9--6.4, *P*=0.095, [Table 3](#tbl3){ref-type="table"}).

Multivariate regression analysis showed that only CXCR7 expression (HR=3.4, 95% CI 1.1--10.5, *P*=0.030), tumour size per mm increase in tumour size (HR=1.1, 95% CI 1.0--1.1, *P*=0.001) and lymph node metastasis at the time of surgery (HR=4.5, 95% CI 1.2--16.8, *P*=0.024) were independent predictors of disease-free survival, when correcting for HPV-type, histopathological diagnosis, tumour size, infiltration depth, parametrial invasion, vasoinvasion, lymph node metastasis, resection margins and postoperative radiotherapy. Multivariate regression analysis for CXCR7, EGFR, CXCR4 and CXCL12 expression showed that only CXCR7 was independently associated with disease-recurrence (HR=4.2, 95% CI 1.5--12.0, *P*=0.007).

Disease-free survival for co-expression of CXCR7, EGFR, CXCR4 and CXCL12
------------------------------------------------------------------------

To assess whether co-expression of CXCR7 and its ligand CXCL12 was associated with disease-free or disease-specific survival, groups were made for CXCR7-negative cases (*n*=58) and CXCR7-positive cases with (*n*=33) or without CXCL12 expression (*n*=5). Survival analysis showed no difference between CXCR7-positive/CXCL12-positive and CXCR7-positive/CXCL12-negative cases (data not shown). To investigate whether co-expression of CXCR7 and EGFR, CXCR4 or both was associated with disease-free or disease-specific survival, groups were made for CXCR7-negative cases (*n*=58), CXCR7-positive cases with no EGFR or CXCR4 expression (single positive, *n*=4), CXCR7-positive cases with either EGFR or CXCR4 expression (double positive, *n*=16) and CXCR7-positive cases with both EGFR and CXCR4 expression (triple positive, *n*=21). As the survival curves for the 4 CXCR7 single-positive cases were comparable to the 58 CXCR7-negative cases, these groups were combined for further analyses. Univariate Cox-regression analysis showed equally increased risks of disease recurrence for both double- and triple-positive cases when compared with CXCR7-negative/single-positive cases (HR=3.6, 95% CI 1.2--10.7, *P*=0.022, and HR=4.2, 95% CI 1.5--11.7, *P*=0.006, respectively, [Figure 2B](#fig2){ref-type="fig"}, [Table 3](#tbl3){ref-type="table"}). As expression of CXCR7 was observed more frequently in squamous cell carcinoma than in other histopathological types, regression analysis was also performed for this subgroup. In squamous cell carcinomas, the risk between disease-free survival and CXCR7-negative/single-positive cases, double-positive cases and triple-positive cases increased in an additive fashion (double: HR=2.7, 95% CI 0.6--12.1, *P*=0.193, triple: HR=5.8, 95% CI 1.5--22.4, *P*=0.011, [Figure 2C](#fig2){ref-type="fig"}, [Table 3](#tbl3){ref-type="table"}). Survival analysis for disease-specific survival showed similar results (data not shown).

Discussion
==========

The present study showed for the first time that CXCR7 was independently associated with disease recurrence in cervical cancer. In addition, CXCR7 expression was associated with tumour size and lymph node status at the time of surgery. These findings suggest that CXCR7 expression leads to more aggressive tumour growth and metastasis formation.

CXC chemokine receptor 7 is frequently expressed on embryonic and neoplastic transformed cells, but undetectable or expressed at very low levels in normal adult tissues ([@bib2]; [@bib15]). Experiments using mouse models showed that increased CXCR7 expression resulted in a larger tumour size and an enhanced metastatic potential ([@bib15]). Previously, CXCR7 has been shown to be associated with disease-specific and disease-free survival in non-small cell lung cancer ([@bib9]). In the present study, we showed that in cervical cancer as well, disease-free survival was lower in CXCR7-positive cases (63%) than in CXCR7-negative cases (90%, HR=4.3, 95% CI 1.7--11.0, *P*=0.002), even when adjusting for other prognostic factors. Disease-specific survival was also strongly associated with CXCR7 expression. Therefore, CXCR7 might be used as a prognostic marker to predict disease recurrence, with additive predictive value to lymph node status and tumour size.

The current data also showed that CXCR7 was often co-expressed with EGFR or CXCR4 (double positive) or both (triple positive), with only four single-positive cases, supporting the hypothesis that CXCR7 requires other molecules for optimal intracellular signalling. [@bib17]) have shown that CXCR7 forms heterodimers with CXCR4 and [@bib18]) have shown that CXCR7 is capable of forming heterodimers with EGFR. Activation of HEK293 cells co-expressing CXCR7 and CXCR4 results in a stronger calcium flux when compared with cells expressing CXCR4 alone, whereas CXCR7 was unable to induce calcium flux by itself ([@bib2]; [@bib17]). However, CXCR7 is capable of signalling through MAPK/AKT pathways, indicating that EGFR, which also signals through MAPK/AKT, might be an alternative co-receptor for CXCR7 ([@bib5]). Interestingly, in CXCR7- and CXCR4-positive rhabdomyosarcoma cells, CXCL12-induced chemotaxis could still be observed after blocking CXCR4, although strongly reduced when compared with controls ([@bib5]). Similarly, in CXCR7-positive, CXCR4-negative 4T1 breast cancer cells, CXCR7 expression promoted tumour growth and progression of lung metastases in mice ([@bib15]). As rhabdomyosarcoma cells and 4T1 breast cancer cells are both EGFR-positive, CXCR7 might signal through heterodimerisation with EGFR in case CXCR4 is absent or blocked ([@bib4]; [@bib8]). However, although our data support this hypothesis, as a positive correlation was observed between CXCR7 and EGFR expression, functional studies on cervical cancer cell lines are required to determine whether CXCR7 and EGFR are indeed co-dependent for signal transduction. Furthermore, although HRs were similar for double- and triple-positive cases in the whole study group, HRs increased in an additive fashion in squamous cell carcinomas, which indicates that molecular mechanisms regulating metastasis formation may differ between histopathological subtypes.

In conclusion, CXCR7 expression was strongly associated with tumour size, lymph node metastasis, disease recurrence and poor disease-specific survival, suggesting that CXCR7 expression leads to a biologically more aggressive tumour. CXC chemokine receptor 7 might be a promising new prognostic marker in cervical cancer and may serve as a potential therapeutic target. CXC chemokine receptor 7 is often co-expressed with CXCR4 and/or EGFR, which supports the hypothesis that these receptors assist in CXCR7 signal transduction.
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###### CXCR7, EGFR, CXCR4 and CXCL12 expression in cervical cancer patients

  **Expression**   ***N*** **(%)**[a](#t1-fn2){ref-type="fn"}
  ---------------- --------------------------------------------
  *CXCR7*          
   Negative        58 (57)
   Weak            18 (18)
   Moderate        20 (20)
   Strong          5 (5)
                    
  *EGFR*           
   Negative        19 (20)
   Weak            16 (17)
   Moderate        31 (33)
   Strong          28 (30)
                    
  *CXCR4*          
   Negative        36 (37)
   Weak            51 (53)
   Moderate        10 (10)
   Strong          0 (0)
                    
  *CXCL12*         
   Negative        13 (14)
   Weak            35 (38)
   Moderate        28 (31)
   Strong          16 (17)

Abbreviations: CXCR=CXC chemokine receptor; EGFR=epidermal growth factor receptor.

Total number of assessed cases is 101 for CXCR7, 94 for EGFR, 97 for CXCR4 and 92 for CXCL12. Protein expression was determined through analysis of an immunohistochemically stained tissue array, as described in the Materials and Methods section. Immunoreactivity was scored as negative, weak, moderate or strong staining intensity.

###### Disease-free survival for clinicopathological parameters

  **Variables**                  ***N***[a](#t2-fn2){ref-type="fn"}   **DFS (%)**   **HR**   **95% CI**   ***P*****-value**
  ------------------------------ ------------------------------------ ------------- -------- ------------ -------------------
  *HPV-type*                                                                                              
   Negative                      9                                    89            ---      ---          ---
   16                            54                                   76            2.2      0.3--16.3    0.465
   18                            23                                   65            3.7      0.5--29.7    0.216
   Other                         17                                   88            1.1      0.1--12.0    0.944
                                                                                                           
  *Histopathology*                                                                                        
   SCC                           62                                   74            0.7      0.3--1.7     0.447
   A(S)                          41                                   81                                   
                                                                                                           
  *Tumour size*                                                                                           
   \<40 mm                       59                                   90            6.1      2.4--15.6    **\<0.001**
   ⩾40 mm                        38                                   55                                   
                                                                                                           
  *Infiltration depth*                                                                                    
   \<15 mm                       56                                   88            3.7      1.5--9.0     **0.003**
   ⩾15 mm                        46                                   63                                   
                                                                                                           
  *Parametrial invasion*                                                                                  
   Negative                      94                                   81            5.2      2.0--13.1    **0.001**
   Positive                      9                                    33                                   
                                                                                                           
  *Vasoinvasion*                                                                                          
   Negative                      48                                   83            2.1      0.9--4.9     0.086
   Positive                      52                                   69                                   
                                                                                                           
  *Lymph node metastasis*                                                                                 
   Negative                      79                                   87            7.2      3.2--16.3    **\<0.001**
   Positive                      24                                   42                                   
                                                                                                           
  *Resections margins*                                                                                    
   Negative                      77                                   83            3.0      1.4--6.8     **0.007**
   Positive                      26                                   58                                   
                                                                                                           
  *Postoperative radiotherapy*                                                                            
   No                            47                                   92            5.1      1.7--15.0    **0.003**
   Yes                           56                                   64                                   

Abbreviations: A(S)=adeno(squamous) carcinoma; DFS=disease-free survival; HR=hazard ratio; 95% CI=95% confidence interval; HPV=human papillomavirus; SCC=squamous cell carcinoma. Univariate Cox-regression analysis for disease-free survival based on clinicopathological parameters.

Total number of cases=103; for some variables, data were not available for all patients. The bold entries place emphasis on statistically significant *P*-values.

###### Disease-free survival for CXCR7, EGFR, CXCR4 and CXCL12 protein expression

  **Variables**                      ***N*** [a](#t3-fn2){ref-type="fn"}   **DFS (%)**   **HR**   **95% CI**   ***P*****-value**
  --------------------------------- ------------------------------------- ------------- -------- ------------ -------------------
  *CXCR7*                                                                                                     
   Negative                                          58                        90         4.3     1.7--11.0        **0.002**
   Positive                                          43                        63                                       
                                                                                                                        
  *EGFR*                                                                                                      
   Low                                               35                        86         2.3      0.9--6.4          0.095
   High                                              59                        71                                       
                                                                                                                        
  *CXCR4*                                                                                                     
   Negative                                          36                        78         1.2      0.5--2.9          0.625
   Positive                                          61                        74                                       
                                                                                                                        
  *CXCL12*                                                                                                    
   Negative                                          13                        69         0.8      0.3--2.3          0.653
   Positive                                          79                        75                                       
                                                                                                                        
  *CXCR7/EGFR/CXCR4*                                                                                          
   CXCR7 negative/single positive                    62                        89         ---        ---              ---
   Double positive                                   16                        63         3.6     1.2--10.7        **0.022**
   Triple positive                                   21                        62         4.2     1.5--11.7        **0.006**
                                                                                                                        
  *CXCR7/EGFR/CXCR4 in SCC*                                                                                   
   CXCR7 negative/single positive                    30                        90         ---        ---              ---
   Double positive                                   14                        71         2.7     0.6--12.1          0.193
   Triple positive                                   16                        56         5.8     1.5--22.4        **0.011**

Abbreviations: CXCR=CXC chemokine receptor; DFS=disease-free survival; EGFR=epidermal growth factor receptor; HR=hazard ratio; 95% CI=95% confidence interval; SCC=squamous cell carcinoma.

Total number of cases=103; for some variables, data were not available for all patients. Univariate Cox-regression analysis for disease-free survival based on the status of CXCR7, EGFR, CXCR4 and/or CXCL12 protein expression. CXCR7, CXCR4 and CXCL12 expression are divided into negative (intensity score of 0) and positive (intensity scores of 1, 2 and 3) groups. EGFR expression was divided into low (intensity scores of 0 and 1) and high (intensity scores of 2 and 3) expression groups. In addition, co-expression of CXCR7, EGFR and CXCR4 was analysed as follows: CXCR7-negative cases (*n*=58) and CXCR7 single-positive cases (*n*=4) were combined and compared with double-positive cases (i.e. CXCR7-positive cases with either high EGFR expression or positive CXCR4 expression), and triple positive cases (i.e. CXCR7-positive cases with both high EGFR expression and positive CXCR4 expression). This analysis was also performed after selection of patients with SCC. The bold entries place emphasis on statistically significant *P*-values.
